{"filing":{"accession_number":"0001193125-26-276103","cik":"0001585608","ticker":"JAGX","company_name":"Jaguar Health, Inc.","form":"8-K","filing_date":"2026-06-18","report_date":null,"primary_document":"d111863d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526276103/d111863d8k.htm"},"events":[{"id":11991,"run_id":10552,"accession_number":"0001193125-26-276103","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Jaguar Health entered into multiple material definitive agreements on June 17-18, 2026, including amendments to royalty interests and promissory notes with Streeterville and Uptown Capital, as well as three exchange transactions converting Series Q Preferred Stock into common stock. These transactions represent a significant restructuring of the Company's capital structure.","company_name":"Jaguar Health, Inc.","ticker":"JAGX","filing_date":"2026-06-18","form":"8-K","submitted_at":null,"items":[{"id":8721,"accession_number":"0001193125-26-276103","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The filing discloses multiple material definitive agreements entered into on June 17-18, 2026, including amendments to royalty interests and promissory notes with Streeterville and Uptown Capital, as well as three exchange transactions converting Series Q Preferred Stock into common stock. The exchange transactions alone resulted in issuance of over 5% of outstanding common shares (34,798 + 36,796 + 38,655 shares), which constitutes a dilutive issuance material to investors. While the royalty amendments primarily extend payment dates and establish minimum monthly payments, the exchange transactions represent a significant restructuring of the Company's capital structure with Streeterville.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T21:17:12.925096+00:00","company_name":"","ticker":null,"filing_date":""},{"id":8722,"accession_number":"0001193125-26-276103","item_number":"2.03","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"Item 2.03 discloses creation of direct financial obligations through amendments to royalty interests and notes, incorporated by reference from Item 1.01. Without access to the full Item 1.01 details, the nature of these obligations cannot be precisely determined—they could represent debt covenant modifications, royalty payment restructurings, or other financial arrangements. The disclosure is material as it creates new or modified financial obligations, but the specific event type (covenant_breach, ma_activity, or other_material) depends on whether these amendments address defaults, represent acquisition-related payments, or constitute standalone restructurings.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T21:17:12.925096+00:00","company_name":"","ticker":null,"filing_date":""},{"id":8723,"accession_number":"0001193125-26-276103","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Item 3.02 explicitly addresses \"Unregistered Sales of Equity Securities\" and incorporates by reference details from Item 1.01 regarding \"Exchange Transactions.\" This structure is characteristic of dilutive equity issuances, particularly private placements or convertible securities. The unregistered nature and reference to exchange transactions signal a material capital-raising event that would affect shareholder equity and ownership dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T21:17:12.925096+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8721,"accession_number":"0001193125-26-276103","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The filing discloses multiple material definitive agreements entered into on June 17-18, 2026, including amendments to royalty interests and promissory notes with Streeterville and Uptown Capital, as well as three exchange transactions converting Series Q Preferred Stock into common stock. The exchange transactions alone resulted in issuance of over 5% of outstanding common shares (34,798 + 36,796 + 38,655 shares), which constitutes a dilutive issuance material to investors. While the royalty amendments primarily extend payment dates and establish minimum monthly payments, the exchange transactions represent a significant restructuring of the Company's capital structure with Streeterville.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T21:17:12.925096+00:00","company_name":"Jaguar Health, Inc.","ticker":"JAGX","filing_date":"2026-06-18"},{"id":8722,"accession_number":"0001193125-26-276103","item_number":"2.03","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"Item 2.03 discloses creation of direct financial obligations through amendments to royalty interests and notes, incorporated by reference from Item 1.01. Without access to the full Item 1.01 details, the nature of these obligations cannot be precisely determined—they could represent debt covenant modifications, royalty payment restructurings, or other financial arrangements. The disclosure is material as it creates new or modified financial obligations, but the specific event type (covenant_breach, ma_activity, or other_material) depends on whether these amendments address defaults, represent acquisition-related payments, or constitute standalone restructurings.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T21:17:12.925096+00:00","company_name":"Jaguar Health, Inc.","ticker":"JAGX","filing_date":"2026-06-18"},{"id":8723,"accession_number":"0001193125-26-276103","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Item 3.02 explicitly addresses \"Unregistered Sales of Equity Securities\" and incorporates by reference details from Item 1.01 regarding \"Exchange Transactions.\" This structure is characteristic of dilutive equity issuances, particularly private placements or convertible securities. The unregistered nature and reference to exchange transactions signal a material capital-raising event that would affect shareholder equity and ownership dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T21:17:12.925096+00:00","company_name":"Jaguar Health, Inc.","ticker":"JAGX","filing_date":"2026-06-18"}]}